A bispecific antibody for certain lymphomas
Mosunetuzumab
A bispecific antibody used to treat some lymphomas by bringing immune cells together with cancer cells.
What is Mosunetuzumab?
Mosunetuzumab is a specialist cancer medicine used to treat certain types of follicular lymphoma that have returned after earlier treatment. It is a bispecific antibody: it grabs hold of the lymphoma cells (through a marker called CD20) with one arm and the body's own T-cells (through CD3) with the other, bringing them together so the immune cells attack the cancer. The most important safety issue is cytokine release syndrome, an over-reaction of the immune system; to reduce this, the first doses are built up gradually (step-up dosing) and given under close observation. It can also cause neurological effects, tumour lysis and infections, and is given only under cancer specialists.
Education and reference only. This is a plain-language guide to Mosunetuzumab — it deliberately contains no doses. Doses depend on the person, the brand and the reason for treatment, and belong with your prescriber. Always check the BNF, the product labelling (SmPC) and follow medical advice.
What it is
Mosunetuzumab is a targeted immunotherapy for certain lymphomas, in particular follicular lymphoma that has come back after at least two earlier treatments. It is a bispecific antibody, meaning it has two binding arms: one attaches to a marker called CD20 on the lymphoma cells, and the other to CD3 on the body's own T-cells (a type of immune cell). By holding the two together, it directs the immune cells to attack the cancer. It is given as a drip into a vein, with the early doses gradually increased to lower the risk of a strong immune reaction, all under the care of a cancer specialist team.
How it works
Mosunetuzumab works by acting as a bridge between cancer cells and the immune system. One arm of the antibody locks onto CD20, a marker on the surface of the lymphoma cells, and the other arm locks onto CD3 on T-cells. Bringing them so close together switches on the T-cells, which then attack and kill the lymphoma cells. Because this powerful immune activation can sometimes be too strong at first, the early doses are deliberately built up step by step, giving the body time to adjust and reducing the risk of cytokine release syndrome. It is given in repeated cycles under close monitoring.
Company & origin
Originated / developed by: Specialist manufacturer.
A specialist cancer medicine used in the UK to treat certain types of follicular lymphoma that have come back after earlier treatment.
Practical use
How to take Mosunetuzumab
General, dose-free guidance — always follow your prescriber's and the leaflet's specific instructions.
- It is given as a drip into a vein by your cancer team, with the first doses built up gradually (step-up dosing).
- Expect close observation around the early doses, as cytokine release syndrome is most likely then.
- Report fever, chills, a fast heartbeat, dizziness or breathlessness straight away, as these can signal a reaction.
- Tell your team promptly about confusion, severe headache, tremor or difficulty speaking.
- Watch for signs of infection and report them quickly, and attend all your monitoring appointments.
Weighing it up
Advantages & disadvantages of Mosunetuzumab
Advantages
- Directs the body's own immune cells to attack lymphoma cells carrying the CD20 marker.
- Offers an option for follicular lymphoma that has come back after earlier treatments.
- Given on a planned cycle with step-up dosing to make early treatment safer.
Disadvantages
- Can cause cytokine release syndrome, an over-reaction of the immune system, especially early on.
- Can cause neurological effects and tumour lysis syndrome from rapid cancer breakdown.
- Increases the risk of infections and is given as a drip under close hospital observation.
Practical use
Good to know
The most important thing to understand about mosunetuzumab is cytokine release syndrome, a reaction where the immune system becomes over-activated, causing fever, chills, a fast heartbeat, low blood pressure, breathlessness or feeling very unwell, usually around the early doses. To reduce this risk, treatment uses step-up dosing, where the first doses are gradually increased, and you are watched closely and may be given medicines to dampen the reaction. It can also cause neurological effects such as confusion, headache, tremor or difficulty speaking, which must be reported promptly, and a condition called tumour lysis syndrome, where the rapid breakdown of cancer cells upsets the body's chemistry, so fluids and blood tests are used. Because it works through the immune system, infections are more likely, and any signs of infection need prompt attention. It is given only under specialist cancer care with close observation.
Who should not take it / use with caution
- People who have had a serious allergic reaction to mosunetuzumab should not have it.
- It is used with particular care in people with active infections, which are usually treated first.
- It is generally avoided in pregnancy and breastfeeding unless a specialist judges it necessary; reliable contraception is advised.
Monitoring
- Close observation around the early step-up doses for signs of cytokine release syndrome.
- Watching for neurological symptoms, infections and tumour lysis syndrome, with blood tests and fluids.
- Regular blood counts and reviews of how the lymphoma is responding over time.
Side effects
- Cytokine release syndrome, with fever, chills, a fast heartbeat, low blood pressure or breathlessness.
- Neurological effects such as confusion, headache, tremor or difficulty speaking.
- Infections, low blood counts, tiredness, rash and tumour lysis syndrome.
- Reactions during the drip, and changes in blood tests that the team watches for.
Key interactions
- Other medicines that weaken the immune system can add to the risk of infection.
- Live vaccines are generally avoided around treatment, as the immune system is affected.
- Tell your team about all your medicines, as other cancer treatments must be coordinated carefully.
Available as: A solution given as a drip into a vein in hospital.
Answers
Mosunetuzumab: frequently asked questions
What is mosunetuzumab used for?
It is used to treat certain types of follicular lymphoma that have come back after earlier treatments, by directing the body's immune cells to attack the cancer.
What is cytokine release syndrome?
It is an over-reaction of the immune system that can cause fever, chills, a fast heartbeat, low blood pressure or breathlessness, most likely around the early doses, which is why those doses are built up gradually.
Why are the first doses built up gradually?
This step-up dosing gives the body time to adjust and lowers the risk of cytokine release syndrome, and you are watched closely during this time.
Can it affect the brain or nerves?
It can cause neurological effects such as confusion, headache, tremor or difficulty speaking, which should be reported to your team promptly.
How is it given?
It is given as a drip into a vein by your cancer team in repeated cycles, with close observation especially during the early doses.
Authoritative sources
- BNF
- NICE CKS
Building a medicines information resource?
We create evidence-led, dose-free drug and formulary references for teams.